Evaluation of three consecutive versions of a commercial rapid PCR test to screen for methicillin-resistant Staphylococcus aureus
| Autor: | Laurence Senn, Dominique S. Blanc, E. Bulliard, Gilbert Greub, Bruno Grandbastien |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Methicillin-Resistant Staphylococcus aureus
0301 basic medicine Microbiology (medical) medicine.medical_specialty 030106 microbiology medicine.disease_cause Polymerase Chain Reaction Sensitivity and Specificity 03 medical and health sciences 0302 clinical medicine Pcr test Internal medicine medicine Humans Mass Screening Bacteriological Techniques/methods Mass Screening/methods Methicillin-Resistant Staphylococcus aureus/genetics Methicillin-Resistant Staphylococcus aureus/isolation & purification Molecular Diagnostic Techniques/methods Polymerase Chain Reaction/methods Staphylococcal Infections/diagnosis Staphylococcal Infections/microbiology Diagnostic test Methicillin-resistant Staphylococcus aureus Performance Rapid PCR test Rapid test Screening 030212 general & internal medicine Bacteriological Techniques business.industry General Medicine Staphylococcal Infections Infectious Diseases Molecular Diagnostic Techniques Staphylococcus aureus business Mrsa screening |
| Zdroj: | Clinical microbiology and infection, vol. 25, no. 11, pp. 1430.e1-1430.e4 |
| ISSN: | 1198-743X |
| DOI: | 10.1016/j.cmi.2019.03.029 |
| Popis: | Objectives Screening for methicillin-resistant Staphylococcus aureus (MRSA) is part of many recommendations to control MRSA. Several rapid PCR tests are available commercially and updated versions are constantly released. We aimed to evaluate the performance of three consecutive versions (G3, Gen3 and NxG) of the XpertMRSA test. Methods Routine samples for MRSA screening were simultaneously tested by culture and rapid PCR. The three versions of XpertMRSA were used successively and compared with culture. Results A total of 3512, 2794 and 3288 samples were analysed by culture and by the G3, Gen3 and NxG XpertMRSA versions, respectively. The rates of positive-by-culture in the three groups were 5.0%, 4.7% and 4.3%, respectively. The sensitivity improved over time (71.4, 95% CI 64.0–77.9; 82.3, 95% CI 74.4–88.2; and 84.3%, 95% CI 77.0–89.7, respectively), but not significantly. The specificity (98.4, 95% CI 97.9–98.8; 96.8, 95% CI 96.0–97.4; and 99.1, 95% CI 98.7–99.4, respectively) and the positive likelihood ratios (45.7, 95% CI 34.4–60.8; 25.6, 95% CI 20.5–32.0; and 97.1, 95% CI 66.3–142.4) were significantly lower in the Gen3 version (p Conclusions These significant differences in performance show the importance of evaluating each new version of a commercial test. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|